Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).
Arcellx (NASDAQ:ACLX) reported quarterly losses of $(39.85) per share. This is a 40.96 percent decrease over losses of $(28.27) per share from the same period last year.